Long Beach, CA
Sales: $104 million
Sales: $104 million. Net income: $12.5 million.
Key Personnel: Steve Carlson, president and chief executive officer; Stephen A. Garcia, chief financial officer.
Major Products: Skin care brands sold under the Obagi brand name. Products include Nu-Derm, C Rx, Professional-C, Nu-Derm Condition and Enhance, Elastiderm eye treatment, Clenziderm M.D. acne therapeutic systems, Clenziderm M.D. Systems for normal to dry skin, Elastiderm Decolletage System, Soluclenz Rx Gel.
New Products: Rosaclear System.
Comments: Corporate sales rose $2 million last year. For the first quarter of 2009, sales fell more than 10% to $22.6 million. Still, the company said its new Rosaclear System was well received. It is billed as the first prescription-based, physician-dispensed system developed specifically for treating the signs and symptoms of rosacea. Rosaclear was introduced in late January and during the quarter contributed $1.3 million in net sales.
Net income in the first quarter tumbled from $3 million to $645,000.
In April, Obagi announced it would focus on the physician-dispensed market and discontinue distribution in the pharmacy channel.